Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022

SELL
$8.42 - $15.32 $101,040 - $183,840
-12,000 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$14.59 - $23.26 $41,669 - $66,430
2,856 Added 31.23%
12,000 $181,000
Q3 2021

Nov 15, 2021

BUY
$15.75 - $30.29 $144,018 - $276,971
9,144 New
9,144 $218,000

Others Institutions Holding CRBU

About Caribou Biosciences, Inc.


  • Ticker CRBU
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,840,800
  • Market Cap $110M
  • Description
  • Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...
More about CRBU
Track This Portfolio

Track Kcl Capital, L.P. Portfolio

Follow Kcl Capital, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kcl Capital, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Kcl Capital, L.P. with notifications on news.